Press Release of Fredun Pharmaceuticals for Q4 and FY25 Robust Performance.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals reported robust Q4 FY25 results, with total income rising 41.8% year-on-year to Rs. 167.4 crore and EBITDA growing 56.2% to Rs. 17.4 crore. Profit after tax for the quarter stood at Rs. 7.1 crore, up 39.7% YoY. For the full year FY25, total income rose 30.7% to Rs. 456.3 crore, EBITDA jumped 41.6% to Rs. 55.1 crore (margin improving to 12.1% from 11.1%), and PAT grew 33.2% to Rs. 20.8 crore. The company also highlighted a highest-ever order book of Rs. 213 crore and secured a Rs. 150–180 crore generic medicines tender from Tamil Nadu Medical Services Corporation. New launches included the FREOSSI Large Animals brand for livestock, the Chuu Balm product, and India's first exclusive pet diagnostic centre, FREDNA VET DIAGNOSTICS.
This is a positive filing for shareholders, with broad-based double-digit growth in revenue, EBITDA, and profit alongside margin expansion. The strong order book, new product launches in veterinary and pet care, and entry into Sri Lanka suggest continued growth momentum, which could support positive investor sentiment.